"Emoxipin" (injections) refers to the pharmacotherapeutic group of antiplatelet agents, antihypoxants and antioxidants. The medication is an angioprotector, corrector of microcirculation. "Emoxipin" (injections) has the ability to reduce the permeability of the vascular wall, blood viscosity and its coagulability. The properties of the drug include strengthening the process of fibrinolysis and improving microcirculation.
"Emoxipin" (injections) is able to effectively inhibit the free radical oxidation of biomembrane lipids, increase the activity of antioxidant enzymes. The medication has an antitoxic effect, a stabilizing effect on cytochrome P-450. When used in extreme cases, which are accompanied by hypoxia and increased lipid peroxidation, the medication is able to optimize bioenergy processes.
The drug "Emoksipin" protects the retina from the negative effects of intense light, promotes resorption of intraocular hemorrhage.
The medication reduces the manifestations of cerebral hemodysfunction, helps increase the resistance of the brain to ischemia and hypoxia. In cases of circulatory disorders of the brain (hemorrhagic and ischemic), it is actively involved in the correction of autonomic dysfunctions and the restoration of cerebral integrative activity.
The medication is able to exert a hypolipidemic effect, reduce the synthesis of triglycerides. The tool has pronounced cardioprotective properties. The medicine "Emoksipin" promotes the expansion of coronary vessels, reduce ischemic damage to the myocardium. In case of myocardial infarction, the medication is able to limit the size of the focus of necrosis, accelerate reparative processes, and normalize myocardial metabolism. "Emoxipin" (injections) has a beneficial effect in the clinical manifestations of myocardial infarction, reducing the incidence of acute heart failure. The medication is involved in the regulation of redox processes with a lack of blood circulation.
The drug is used in ophthalmology in the treatment of central chorioretinal dystrophies, degenerative changes in the retina against a background of high myopia, and diabetic retinopathy. The drug can also be prescribed for occlusion in the central retinal vein and its branches, glaucoma, optic neuropathy of various origins.
"Emoksipin" is used in neurosurgery and neurology for hemorrhagic stroke, ischemic stroke in the vertebrobasilar system and the carotid artery (internal) pool, with transient circulatory disorders in the brain, its chronic failure. The medication is prescribed for traumatic brain injuries, accompanied by brain injuries, in the period after operations associated with craniocerebral injuries, hematomas.
Cardiologists prescribe medication for patients with myocardial infarction (acute) in order to prevent “reperfusion syndrome” and unstable angina pectoris.
In surgery, the drug is used for chronic and acute pancreatitis, peritonitis, including in the preoperative and postoperative period.
The dosage and duration of therapy are prescribed by the doctor individually.
With subconjunctival and retrobulbar administration, pain, burning, redness, itching, and also seals of paraorbital tissues, which dissolve independently, may occur. Intravenous administration may be accompanied by burning along the vessel. In some cases, drowsiness or agitation, an increase in blood pressure are observed. In patients predisposed to allergies, in some cases, reddening of the skin and itching are observed.
The drug is not prescribed during pregnancy and with individual intolerance.
The use of the medication should be accompanied by constant monitoring of blood pressure and blood coagulation.